Prelude Therapeutics grants 230,000 stock options

Prelude Therapeutics reported that Chief Scientific Officer Peggy Scherle received an employee stock option grant on February 4, 2026.

Rhea-AI Filing Summary

Prelude Therapeutics reported that Chief Scientific Officer Peggy Scherle received an employee stock option grant on February 4, 2026. The derivative award covers 230,000 shares of common stock at an exercise price of $2.30 per share, with no cash paid for the option itself.

The option vests over time: 25% of the total shares vest on February 4, 2027, and the remaining shares vest in equal monthly installments of 1/48 of the total until fully vested. Following this grant, Scherle beneficially holds 230,000 stock options, all reported as directly owned.

Insider Trade Summary

Grant/Award: 230,000 shares

Grant/Award 1 txn

Insider Scherle Peggy

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	230,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 230,000 contracts (Direct)

Footnotes (1)

1. F1. The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Prelude Therapeutics (PRLD) report for Peggy Scherle?

Prelude Therapeutics reported that Chief Scientific Officer Peggy Scherle received an employee stock option grant for 230,000 shares. The Form 4 shows this as an acquisition of derivative securities, not a sale of common stock into the market.

How many Prelude Therapeutics (PRLD) options were granted to Peggy Scherle and at what price?

Peggy Scherle was granted employee stock options on 230,000 shares of Prelude Therapeutics common stock. The options carry an exercise price of $2.30 per share, with the option itself reported at a price of $0.00 on the Form 4.

What is the vesting schedule for Peggy Scherle’s Prelude Therapeutics (PRLD) stock options?

The stock option vests 25% of the total shares on February 4, 2027. After that, the remaining shares vest in equal monthly installments of 1/48 of the total until fully vested, contingent on continued service to Prelude Therapeutics.

Is Peggy Scherle’s Prelude Therapeutics (PRLD) option grant reported as direct or indirect ownership?

The Form 4 reports Peggy Scherle’s 230,000 employee stock options as directly owned. No separate trust or entity is listed for this grant, and the nature-of-ownership field does not indicate any indirect holding structure.

Did Peggy Scherle sell any Prelude Therapeutics (PRLD) shares in this Form 4 filing?

No sale of Prelude Therapeutics common stock is reported. The Form 4 discloses an acquisition of employee stock options as a derivative security, with 230,000 options granted and no disposition of underlying common shares indicated.

When do Peggy Scherle’s Prelude Therapeutics (PRLD) options expire if fully vested?

The employee stock options reported in the Form 4 have an expiration date of February 3, 2036. They vest over time beginning February 4, 2027, and remain exercisable until that expiration date, subject to usual employment and plan conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/05/2026 - 04:12 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scherle Peggy

(Last) (First) (Middle)

C/O PRELUDE THERAPEUTICS INCORPORATED

175 INNOVATION BOULEVARD

(Street)

WILMINGTON DE 19805

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Prelude Therapeutics Inc [ PRLD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$2.3	02/04/2026		A		230,000		(1)	02/03/2036	Common Stock	230,000	$0.00	230,000	D

Explanation of Responses:

1. The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Remarks:

	/s/ Bryant D. Lim, Attorney-in-Fact	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.